A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer

November 27, 2019 updated by: AbbVie

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer

This is a Phase 1, first-in-human, dose escalation study in participants with advanced solid tumors to determine the pharmacokinetics, maximum tolerated dose and the recommended Phase 2 dose of ABBV-075 at different monotherapy dosing schedules. In addition the study will evaluate the safety. tolerability and the pharmacokinetics of ABBV-075 monotherapy or combination therapy in disease specific expansion cohorts.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

128

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Arizona
      • Scottsdale, Arizona, United States, 85258-4566
        • Scottsdale Healthcare /ID# 132963
    • California
      • Duarte, California, United States, 91010
        • City of Hope /ID# 154053
      • Sacramento, California, United States, 95817
        • UC Davis Comp Cancer Ctr /ID# 154644
    • Connecticut
      • New Haven, Connecticut, United States, 06510
        • Yale University /ID# 136982
    • Illinois
      • Chicago, Illinois, United States, 60637-1443
        • University of Chicago /ID# 155453
    • Indiana
      • Indianapolis, Indiana, United States, 46202
        • Indiana Univ School Medicine /ID# 132946
    • North Carolina
      • Durham, North Carolina, United States, 27705
        • Duke Univ Med Ctr /ID# 154647
    • Texas
      • Dallas, Texas, United States, 75230
        • Mary Crowley Cancer Research /ID# 154059
      • Houston, Texas, United States, 77030
        • Univ TX, MD Anderson /ID# 132276
      • Houston, Texas, United States, 77030
        • UT MD Anderson Cancer Center /ID# 164122

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Participant in the dose escalation cohorts must have histological confirmation of locally advanced or metastatic solid tumor that is either refractory after standard of care therapy for the disease or for which standard of care therapy or does not exist.
  2. Participants in the expansion cohorts must have histological confirmation of AML, Multiple Myeloma, breast cancer, NSCLC, prostate cancer, SCLC, or NHL that is either refractory after standard of care therapy or for which standard of care therapy does not exist.
  3. Participant must have an Eastern Cooperative Oncology Group (ECOG) Performance status of: 0 - 1 (dose escalation cohorts) or 0 - 2 (expansion cohorts)
  4. Participants in the dose escalation cohort must have a serum albumin of ≥ 3.2 g/dL at screening.
  5. Adequate bone marrow, renal, and hepatic function.
  6. QTc interval < 480 milliseconds (msec) on the baseline electrocardiogram.

Exclusion Criteria:

  1. Participant has untreated brain or meningeal metastases.
  2. Participant has received anti-cancer therapy including chemotherapy, immunotherapy, biologic or any investigational therapy within a period of 21 days prior to Study Day 1.
  3. Participant has active peptic ulcer disease or other hemorrhagic esophagitis/gastritis.
  4. Symptoms of gross hematuria or gross hemoptysis.
  5. Exhibits symptomatic or persistent, uncontrolled hypertension (BP > or = to 140 and/or diastolic pressure of > or = to 90 mm Hg).
  6. History of long QT syndrome.
  7. Peripheral neuropathy greater than or equal to grade 2.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: ABBV-075
Dose escalation cohorts of ABBV-075 monotherapy
Drug: ABBV-075
ABBV-075 Oral tablets
Other Names:
  • Mivebresib
Experimental: ABBV-075 and venetoclax combination
Expansion cohorts of ABBV-075 and venetoclax combination therapy
Drug: ABBV-075
ABBV-075 Oral tablets
Other Names:
  • Mivebresib
Drug: Venetoclax
Venetoclax tablets, film-coated
Other Names:
  • Venclexta
Experimental: ABBV-075 expansion
Expansion cohorts of ABBV-075 monotherapy
Drug: ABBV-075
ABBV-075 Oral tablets
Other Names:
  • Mivebresib

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Maximum Tolerated Dose of ABBV-075
Time Frame: Minimum first cycle of dosing (28 days) up to one year for dose escalation segment.
Maximum tolerated dose is defined as the highest dose level at which less than 2 of 6 participants experience the same dose limiting toxicity. If more than 2 participants experience a different dose limiting toxicity, the maximum tolerated dose may be further evaluated or determined to be exceeded based on discussions with the investigators and medical monitors.
Minimum first cycle of dosing (28 days) up to one year for dose escalation segment.
Time to Cmax (peak time, Tmax) for ABBV-075
Time Frame: Approximately 24 hours following a single dose of ABBV-075 up to approximately 2 years.
Approximately 24 hours following a single dose of ABBV-075 up to approximately 2 years.
Number of participants with adverse events
Time Frame: Screening, Cycle 1 Day 1, 8 and 15, then Day 1 of each cycle up to approximately 2 years.
Screening, Cycle 1 Day 1, 8 and 15, then Day 1 of each cycle up to approximately 2 years.
Maximum observed plasma concentration (Cmax) of ABBV-075
Time Frame: Approximately 24 hours following a single dose of ABBV-075 up to approximately 2 years.
Approximately 24 hours following a single dose of ABBV-075 up to approximately 2 years.
Area under the curve (AUC)
Time Frame: Cycle 1 Day 1 Pre-dose, 1, 2, 3, 4, 6, 8 and 24 hours post ABBV-075 dosing, and on Cycle 1 Day 15 at 14, 17, 20 hours post dose.
Area under the plasma concentration versus time curve from time 0 (pre-dose) to the time of the last measurable concentration (AUC 0-t).
Cycle 1 Day 1 Pre-dose, 1, 2, 3, 4, 6, 8 and 24 hours post ABBV-075 dosing, and on Cycle 1 Day 15 at 14, 17, 20 hours post dose.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Duration of overall response (DOR)
Time Frame: At screening, every 8 weeks from Cycle 1 Day 1, and at the Final visit up to approximately 2 years.
DOR is defined as the time from the participant's initial CR or PR to the time of disease progression
At screening, every 8 weeks from Cycle 1 Day 1, and at the Final visit up to approximately 2 years.
Objective Response Rate (ORR)
Time Frame: At screening, every 8 weeks from Cycle 1 Day 1, and at the Final visit up to approximately 2 years.
ORR is defined as the proportion of participants who have a complete response (CR) or partial response (PR).
At screening, every 8 weeks from Cycle 1 Day 1, and at the Final visit up to approximately 2 years.
Progression Free Survival (PFS)
Time Frame: Screening, every 8 weeks from Cycle 1 Day 1, and at the Final visit up to approximately 2 years.
PFS is defined as the time from the first dose of ABBV-075 to either disease progression or death, whichever occurs first.
Screening, every 8 weeks from Cycle 1 Day 1, and at the Final visit up to approximately 2 years.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

AbbVie

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 14, 2015

Primary Completion (Actual)

July 5, 2019

Study Completion (Actual)

July 5, 2019

Study Registration Dates

First Submitted

March 12, 2015

First Submitted That Met QC Criteria

March 12, 2015

First Posted (Estimate)

March 18, 2015

Study Record Updates

Last Update Posted (Actual)

November 29, 2019

Last Update Submitted That Met QC Criteria

November 27, 2019

Last Verified

July 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • M14-546

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer

Clinical Trials on ABBV-075

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe